Cyclic vs Linear Peptides: Why the Ring Changes Things

A cyclic peptide is a chain joined back to itself. The change sounds cosmetic and is not: closing the ring alters the mass, the stability, the behaviour on a column, and what an identity measurement can and cannot settle.

Three ways to close a ring

Head to tail. The amino terminus joins the carboxyl terminus, leaving a continuous backbone with no free ends at all.
Side chain to side chain. Two side chains several positions apart are joined, most often as a lactam between an amine on one and a carboxyl on the other. The backbone keeps its ends; the loop sits inside the molecule.
Disulfide. Two cysteine side chains are oxidised together. This one is reversible, which matters below.

Peptides in this catalogue that are cyclic, such as PT-141, use the side-chain lactam route. A lactam is an ordinary amide bond, the same kind that links the backbone, built in a different place.

The mass changes, and by a known amount

Joining an amine to a carboxyl releases a water, so a peptide closed by a lactam or head to tail weighs about eighteen daltons less than the linear precursor it came from. A disulfide is different: it removes two hydrogens, about two daltons.

Both differences are easy to measure, so a mass check confirms that cyclisation happened. That is the part a mass measurement settles cleanly.

What it cannot settle

If more than one pair of side chains could have reacted, every possible product has the same formula and the same mass. A single mass measurement cannot say where the ring closed. Distinguishing the alternatives requires fragmenting the molecule and reading the pieces, which is what tandem mass spectrometry provides.

This is the reason a certificate for a cyclic peptide is carrying more than it appears to when it reports a matching mass. The number answers a real question and not every question.

What the constraint buys

A linear chain samples an enormous number of shapes. Closing it removes most of them, so the molecule spends its time in a narrower set of conformations. That is the point of making one: a constrained shape is a defined shape.

Removing the chain ends has a second effect. Enzymes that degrade peptides by chewing inward from a free terminus have nothing to grip on a head-to-tail cycle, so cyclic peptides are generally more resistant to that route. The strategy is well documented across the field. (Reference: White & Yudin, 2011)

Constraint was also the design move that produced the potent melanocortin analogues of the late 1980s, which is where several compounds in this family trace their structure. (Reference: Al-Obeidi et al., 1989)

Nature does it too

Cyclic peptides are not only a laboratory trick. Plants make head-to-tail cyclic peptides with internal disulfides that are unusually resistant to heat and to enzymes, and those natural products are studied partly as evidence of how much stability the topology can deliver. (Reference: Craik et al., 2001)

Size sets the difficulty

Not all rings are equally easy to close. Very small cycles strain the bond angles, and very large ones give the two ends too much room to find each other, so the ends spend their time apart. The sizes in between close most readily, and a chemist choosing where to put a bridge is partly choosing a ring size that cooperates.

The position of the bridge also decides how much of the chain is inside the loop. A bridge between residues two and seven constrains a different portion of the molecule than one between residues one and eight, even though both produce a cyclic peptide by the same chemistry. (Reference: White & Yudin, 2011)

Partly cyclic is a real category

A molecule can carry a ring and still have free ends, which is what a side-chain bridge produces. Descriptions sometimes call this cyclic without qualification, and the difference matters: a head-to-tail cycle has no terminus for an enzyme to attack, while a side-chain bridge leaves both termini exposed.

Reading a specification, the useful question is not whether the word cyclic appears but which atoms were joined.

Making one is harder than making a chain

The linear sequence is ordinary solid-phase synthesis. The closure is an extra step with its own yield, and it competes with an unwanted reaction: at high concentration, chains join to each other instead of closing on themselves, producing dimers and larger species.

Two approaches manage that. Closing the ring while the chain is still attached to the resin keeps chains physically separated, so each is more likely to find its own other end. Closing it in solution achieves the same effect by working dilute, which means large volumes for small amounts of product. Either way, whatever failed to cyclise is still present when purification begins. (Reference: White & Yudin, 2011)

On a column they behave differently

A constrained molecule presents a different surface than the open chain, so retention time on a reversed-phase column is not predictable from the sequence alone. The uncyclised precursor and the product usually separate, which is useful, since it means the purity measurement sees the failure.

Storage follows the same logic as any dry peptide, with one addition: a compound held closed by a disulfide should be kept away from conditions that reduce it, since the ring is only as durable as the bond holding it. Our guide to storing research peptides covers the general case.

Reading a specification

A specification that says cyclic should say how: head to tail, a named side-chain bridge, or a disulfide. The three give different masses and different stabilities, and a disulfide can be reduced and reopened while a lactam cannot. Whatever it says, the material is established by the certificate and a batch you can check.

Check this against a real batch

Every compound in the catalog lists its formula, molecular weight and CAS number, and every batch we ship has a certificate you can look up by number.

Frequently asked questions

What makes a peptide cyclic?

The chain is joined back to itself: amino terminus to carboxyl terminus, one side chain to another, or two cysteines oxidised into a disulfide. Each route gives a different structure and a different mass change.

How much does cyclisation change the mass?

Joining an amine to a carboxyl releases a water, so the product is about eighteen daltons lighter than the linear precursor. A disulfide instead removes two hydrogens, about two daltons.

Can mass spectrometry confirm where a peptide cyclised?

Not from a single mass measurement. If more than one pair of side chains could have reacted, every product has the same formula and mass. Telling them apart requires fragmenting the molecule, which tandem mass spectrometry does.

Why make a cyclic peptide at all?

A linear chain samples many shapes and a closed one samples far fewer, so the constraint gives a defined shape. Removing free chain ends also makes the molecule more resistant to enzymes that degrade peptides from a terminus.

What goes wrong when a peptide is cyclised?

At high concentration chains react with each other instead of closing on themselves, producing dimers and larger species. Closing on the resin or working dilute in solution reduces that, and whatever failed to cyclise remains for purification to remove.

Is a disulfide the same as a lactam bridge?

No. A disulfide can be reduced and reopened, so the constraint does not hold under reducing conditions. A lactam is an amide bond like those in the backbone and does not come apart that way.